AstraZeneca grants Circassia Pharmaceuticals marketing rights in the US for Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide + formoterol) to treat COPD.
AstraZeneca has announced it has entered a strategic collaboration with Circassia Pharmaceuticals plc, a respiratory biopharmaceutical company, for the development and commercialisation of Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide + formoterol) in the US. Tudorza and Duaklir are inhaled respiratory medicines for the treatment of chronic obstructive pulmonary disease (COPD).
Tudorza was approved and launched in the US in 2012. Duaklir is expected to be submitted for US regulatory review in 2018. Under the terms of the collaboration, Circassia will lead the promotion of Tudorza in the US and has been granted an option to gain the full commercial rights in the future. Circassia has also been granted the rights to Duaklir in the US. AstraZeneca will receive a minority equity stake in Circassia. AstraZeneca will complete ongoing development activities and continue to manufacture and supply both medicines.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins